首站-论文投稿智能助手
典型文献
The adipokine orosomucoid alleviates adipose tissue fibrosis via the AMPK pathway
文献摘要:
The excess deposition of underlying extracellular matrix(ECM)in adipose tissue is defined as adipose tissue fibrosis that is a major contributor to metabolic disorder such as obesity and type 2 diabetes.Anti-fibrosis therapy has received much attention in the treatment of metabolic disorders.Orosomucoid(ORM)is an acute-phase protein mainly produced by liver,which is also an adipokine.In this study,we investigated the effects of ORM on adipose tissue fibrosis and the potential mechanisms.We showed that ORM 1-deficient mice exhibited an obese phenotype,manifested by excessive collagen deposition in adipose tissues and elevated expression of ECM regulators such as metalloproteinases(MMP-2,MMP-13,MMP-14)and tissue inhibitors of metalloproteinases(TIMP-1,TIMP-2,TIMP-3).Administration of exogenous ORM(50mg·kg-1·d-1,ip)for 7 consecutive days in high-fat diet(HFD)-fed mice and leptin receptor(LepR)-deficient db/db mice attenuated these abnormal expressions.Meanwhile,ORM administration stimulated AMP-activated protein kinase(AMPK)phosphorylation and decreased transforming growth factor-β1(TGF-β1)level in adipose tissues of the mice.In TGF-β1-treated 3T3-L1 fibroblasts,ORM(10 μg/mL)improved the impaired expression profiles of fibrosis-related genes,whereas a selective AMPK inhibitor dorsomorphin(1 μmol/mL)abolished these effects.Together,our results suggest that ORM exerts a direct anti-fibrosis effect in adipose tissue via AMPK activation.ORM is expected to become a novel target for the treatment of adipose tissue fibrosis.
文献关键词:
作者姓名:
Peng-yuan Wang;Jia-yi Feng;Zhen Zhang;Yi Chen;Zhen Qin;Xian-min Dai;Jie Wei;Bo-han Hu;Wei-dong Zhang;Yang Sun;Xia Liu
作者机构:
School of Pharmacy,Second Military Medical University/Naval Medical University,Shanghai 200433,China
引用格式:
[1]Peng-yuan Wang;Jia-yi Feng;Zhen Zhang;Yi Chen;Zhen Qin;Xian-min Dai;Jie Wei;Bo-han Hu;Wei-dong Zhang;Yang Sun;Xia Liu-.The adipokine orosomucoid alleviates adipose tissue fibrosis via the AMPK pathway)[J].中国药理学报(英文版),2022(02):367-375
A类:
orosomucoid,Orosomucoid
B类:
adipokine,alleviates,adipose,fibrosis,AMPK,pathway,deposition,underlying,extracellular,matrix,ECM,defined,that,major,contributor,metabolic,such,obesity,diabetes,Anti,therapy,received,much,attention,treatment,disorders,ORM,acute,phase,mainly,produced,by,liver,which,also,In,this,study,investigated,effects,potential,mechanisms,We,showed,deficient,mice,exhibited,obese,phenotype,manifested,excessive,collagen,tissues,elevated,regulators,metalloproteinases,MMP,inhibitors,TIMP,Administration,exogenous,50mg,consecutive,days,high,fat,diet,HFD,fed,leptin,receptor,LepR,db,attenuated,these,abnormal,expressions,Meanwhile,administration,stimulated,activated,kinase,phosphorylation,decreased,transforming,growth,TGF,level,treated,3T3,L1,fibroblasts,improved,impaired,profiles,related,genes,whereas,selective,dorsomorphin,abolished,Together,our,results,suggest,exerts,direct,anti,activation,expected,become,novel,target
AB值:
0.524742
相似文献
Novel soybean peptide iglycin ameliorates insulin resistance of high-fat diet fed C57BL/6J mice and differentiated 3T3L1 adipocytes with improvement of insulin signaling and mitochondrial function
Yinghuan Wu;Ran Zhao;Minxia Li;Huiyun Li;Zhengwang Chen;Yanying Zhao-Key Laboratory of Qinghai-Tibetan Plateau Animal Genetic Resource Reservation and Utilization of Ministry of Education,Key Laboratory of Qinghai-Tibetan Plateau Animal Genetic Resource Reservation and Utilization of Sichuan Province,College of Life Science and Technology,Southwest Minzu University,Chengdu 610041,China;Shandong Tianheng Inspection Co.,Ltd.,Heze 274000,China;Key Laboratory of Molecular Biophysics of Ministry of Education,School of Life Science and Technology,Huazhong University of Science and Technology,Wuhan 430074,China
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
Nuclear UHRF1 is a gate-keeper of cellular AMPK activity and function
Xiang Xu;Guangjin Ding;Caizhi Liu;Yuhan Ding;Xiaoxin Chen;Xiaoli Huang;Chen-Song Zhang;Shanxin Lu;Yunpeng Zhang;Yuanyong Huang;Zhaosu Chen;Wei Wei;Lujian Liao;Shu-Hai Lin;Jingya Li;Wei Liu;Jiwen Li;Sheng-Cai Lin;Xinran Ma;Jiemin Wong-Shanghai Key Laboratory of Regulatory Biology,Institute of Biomedical Sciences and School of Life Sciences,East China Normal University,Shanghai,China;Zhongshan-Xuhui Hospital,Fudan University and Shanghai Key Laboratory of Medical Epigenetics,the International Co-laboratory of Medical Epigenetics and Metabolism,Ministry of Science and Technology,Institutes of Biomedical Sciences,Fudan University,Shanghai,China;Department of Biochemistry and Department of Cardiology of the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;State Key Laboratory of Cellular Stress Biology,Innovation Center for Cell Signaling Network,School of Life Sciences,Xiamen University,4221 South Xiang'an Road,Xiamen,Fujian,China;State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,University of Chinese Academy of Sciences,Chinese Academy of Sciences,Shanghai,China;Department of Biochemistry and Molecular Biology,Program in Molecular and Cell Biology,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China;Joint Center for Translational Medicine,Fengxian District Central Hospital,6600 Nanfeng Road,Shanghai,China
LncRNA DACH1 protects against pulmonary fibrosis by binding to SRSF1 to suppress CTNNB1 accumulation
Jian Sun;Tongzhu Jin;Zhihui Niu;Jiayu Guo;Yingying Guo;Ruoxuan Yang;Qianqian Wang;Huiying Gao;Yuhan Zhang;Tianyu Li;Wenxin He;Zhixin Li;Wenchao Ma;Wei Su;Liangliang Li;Xingxing Fan;Hongli Shan;Haihai Liang-Department of Pharmacology(State-Province Key Laboratories of Biomedicine-Pharmaceutics of China,Key Laboratory of Cardiovascular Research,Ministry of Education),College of Pharmacy,Harbin Medical University,Harbin 150081,China;Northern Translational Medicine Research and Cooperation Center,Heilongjiang Academy of Medical Sciences,Harbin Medical University,Harbin 150081,China;Zhuhai People's Hospital,Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment,Zhuhai Hospital Affiliated with Jinan University,Jinan University,Zhuhai 519000,China;Department of Thoracic Surgery,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China;State Key Laboratory of Quality Research in Chinese Medicine/Macau Institute for Applied Research in Medicine and Health,Macau University of Science and Technology,Macau(SAR),China;Research Unit of Noninfectious Chronic Diseases in Frigid Zone(2019RU070),Chinese Academy of Medical Sciences,Harbin 150081,China
Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease
Jie Tong;Dongjie Li;Hongbo Meng;Diyang Sun;Xiuting Lan;Min Ni;Jiawei Ma;Feiyan Zeng;Sijia Sun;Jiangtao Fu;Guoqiang Li;Qingxin Ji;Guoyan Zhang;Qirui Shen;Yuanyuan Wang;Jiahui Zhu;Yi Zhao;Xujie Wang;Yi Liu;Shenxi Ouyang;Chunquan Sheng;Fuming Shen;Pei Wang-Department of Pharmacy,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Institute of Nuclear Medicine,Tongji University School of Medicine,Shanghai 200072,China;Department of General Surgery,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Department of Pharmacology,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China;Department of Pharmacy,Shanghai Fourth People's Hospital,Tongji University School of Medicine,Shanghai 200081,China;Shanghai Key Laboratory of Regulatory Biology,Institute of Biomedical Sciences and School of Life Sciences,East China Normal University,Shanghai 200241,China;Chemical Biology Research Center School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325000,China;Department of Medicinal Chemistry,School of Pharmacy,Naval Medical University/Second Military Medical University,Shanghai 200433,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。